Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Baxter, Coherus pen biosimilars deal; terminated

Executive Summary

Baxter International Inc. and biosimilars-focused Coherus BioSciences Inc. have teamed up to develop and commercialize a biosimilar formulation of etanercept in Europe, Canada, Brazil, and certain other markets. The deal term is ten years, subject to possible three-year extensions on a country-by-country basis.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies